Annual Reports in Medicinal Chemistry

Series Editor:

  • Manoj Desai, Gilead Sciences, Inc., Foster City, CA, USA

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.
View full description


medicinal, pharmaceutical, and organic chemists


Book information

  • Published: October 2013
  • ISBN: 978-0-12-417150-3


"This series is one of the very few annual publications which justify the title of an absolute must for the pharmacologist, chemist, or physician who is interested in the chemistry of drug development."--ENZYMOLOGIA

Table of Contents

  1. Challenges in Drug Discovery at Schering-Plough Research Institute: A Personal Reflection
  2. My Perspective on Time, Managers-and Scientific Fun
  3. A Career in Medicinal Chemistry - A Journey in Drug Discovery
  4. Selective Inhibitors of PDE2, PDE9 and PDE10 - Modulators of Activity of the Central Nervous System
  5. Beyond Secretases: Kinases Inhibitors for the Treatment of Alzheimer’s Disease
  6. Orexin Receptor Antagonists in Development for Insomnia and CNS Disorders
  7. Discovery and Development of Prolylcarboxypeptidase (PRCP) Inhibitors for Cardiometabolic Disorders
  8. Molecular Targeting of Imaging and Drug Delivery Probes in Atherosclerosis
  9. Oral GLP-1 Modulators for the Treatment of Diabetes
  10. Recent Advances in the Discovery and Development of CCR1 Antagonists
  11. Emerging Targets for the Treatment of Idiopathic Pulmonary Fibrosis
  12. Targeting the Nuclear Hormone Receptor RORgt for the Treatment of Autoimmune and Inflammatory Disorders
  13. Recent Advances in Small-Molecule Modulation of Epigenetic Targets: Discovery and Development of Histone Methyltransferase- and Bromodomain Inhibitors
  14. Inhibition of Ubiquitin Proteasome System Enzymes for Anticancer Therapy
  15. Targeting Protein-Protein Interactions to Treat Cancer-Recent Progress and Future Directions
  16. Recent Progress in the Discovery of Neuraminidase Inhibitors as Anti-influenza Agents
  17. Novel Therapeutics in Discovery and Development for Treatment of Chronic HBV Infection
  18. Special Challenges to the Rational Design of Antibacterial Agents
  19. Recent Advances in Small Molecule Target Identification Methods
  20. Neuroinflammation in Mood Disorders: Mechanisms and Drug Targets
  21. Inhibitors of hERG Channel Trafficking-A Cryptic Mechanism For QT Prolongation
  22. Recent Progress in Small-Molecule Agents Against Age-Related Macular Degeneration
  23. Synthetic Macrocycles in Small-Molecule Drug Discovery
  24. Glossary of Terms Used in Medicinal Chemistry Part II (IUPAC Recommendations 2011)
  25. Case History: XalkoriTM (Crizotinib), a Potent and Selective Dual Inhibitor of MET and ALK for Cancer Treatment
  26. Case History: Vemurafenib, a Potent, Selective, and First-in-Class Inhibitor of Mutant BRAF for the Treatment of Metastatic Melanoma
  27. New Chemical Entities Entering Phase III Trials in 2012

    28. To Market, to Market-2012